A genetic test known as chromosomal microarray analysis (CMA) could help identify the cause of sudden infant death syndrome (SIDS) or its counterpart in older children, known as sudden unexplained ...

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Variantyx, a leader in genomic precision medicine, today announced the launch of its IriSight™ CNV Analysis - a whole genome-based test for the detection of ...

New York, NY—A large, multi-center clinical trial led by researchers from Columbia University Medical Center (CUMC) shows that a new genetic test resulted in significantly more clinically relevant ...

(MENAFN- EIN Presswire) EINPresswire/ -- "The chromosomal microarray reflex testing market is witnessing significant growth as advancements in genetic diagnostics continue to transform healthcare.

A genetic test known as chromosomal microarray analysis (CMA) could help identify the cause of sudden infant death syndrome (SIDS) or its counterpart in older children, known as sudden unexplained ...

An international consortium of genetics experts has issued a consensus statement recommending chromosomal microarray (CMA) as the new standard practice for genetic evaluation of children with ...

Researchers have identified pathogenic gene variations in 12% of cases of sudden unexplained death in children. The new study, which involved 116 cases of sudden infant death syndrome (SIDS) or sudden ...

Thermo Fisher Scientific, Inc. TMO recently launched the Applied Biosystems CytoScan HD Accel array — a new chromosomal microarray intended to enhance cytogenetic research lab productivity, efficiency ...

Advancements in technologies have revolutionized the genetic landscape. Chromosomal microarray analysis (CMA) becomes a proven method and is implemented to detect gains and losses of DNA and absence ...

Each month, The Clinical Advisor makes one new clinical feature available ahead of print. Don’t forget to take the poll. The results will be published in the next month’s issue. Healthcare providers ...